Similar articles

• [Complications in treatment with beta blockader Practolol (Eraldin)].

  Brinck HP, Aasved H, Jacobsen KB. Brinck HP, et al. Tidsskr Nor Laegeforen. 1975 Aug 30;95(24):1357-9, 1352. Tidsskr Nor Laegeforen. 1975. PMID: 126503 Norwegian. No abstract available.
• Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin).

  Sondergaard J, Wadskov S, Jensen HA, Mikkelsen HI. Sondergaard J, et al. Acta Derm Venereol. 1976;56(3):239-43. Acta Derm Venereol. 1976. PMID: 59510
• [Sclerosing peritonitis and practolol (Eraldin)].

  Algaard A, Knudsen O, Solheim KE. Algaard A, et al. Tidsskr Nor Laegeforen. 1976 Apr 30;96(12):696-7. Tidsskr Nor Laegeforen. 1976. PMID: 936122 Norwegian. No abstract available.
• Perspectives in dermatology: Great Britain (1972-1974).

  Mackie RM, Milne JA. Mackie RM, et al. Int J Dermatol. 1975 Dec;14(10):727-32. doi: 10.1111/j.1365-4362.1975.tb00089.x. Int J Dermatol. 1975. PMID: 127751 Review. No abstract available.
• Immunological aspects of practolol toxicity.

  Amos HE. Amos HE. Int J Immunopharmacol. 1979;1(1):9-16. doi: 10.1016/0192-0561(79)90025-0. Int J Immunopharmacol. 1979. PMID: 399251 Review.